CTLA4 and melanoma: To date, the US Food and Drug Administration has approved the following 3 ICIs for the treatment for advanced melanoma: ipilimumab (cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] inhibitor), pembrolizumab, and nivolumab (programmed cell death protein 1 [PD-1] inhibitors).